title: [Be cautious of using anti-vascular endothelial growth factor therapy for treatment of macular edema secondary to retinal vein occlusion].
abstract: There are various therapies for the treatment of macular edema secondary to retinal vein occlusion (RVO). Intravitreous injection of anti-vascular endothelial growth factor (VEGF) is a new procedure. The efficacy and safety of this therapy have been widely proved in short term clinical observations. However, the relapse of macular edema and the requirement for multi-injections are still remaining problems. It requires more evidences to prove that a better long term prognosis could be obtained from this procedure as compared with traditional laser coagulation. The optimizing therapies should include a combination of anti-VEGF therapy with other drugs and laser treatment to decrease the risk of multi-injections and to obtain the best results. Selection of appropriate therapeutic procedure (based on the evidence based medicine) to protect and improve visual function are the important project of clinicians and require further exploration and investigation.
authors.affiliation: First People's Hospital of Shanghai Jiaotong University, Shanghai 200080, China. sun_xiaodong@hotmail.com
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Sun
authors.forename: Yuan-yuan
authors.initials: YY
authors.lastname: Gong
authors.forename: Feng-hua
authors.initials: FH
authors.lastname: Wang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000075202:Contraindications; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A